Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Announces Positive Research Results for PharmaPatch(TM) with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

GlobeNewswire July 18, 2023

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX(TM) (racemic ketamine) to the FDA

GlobeNewswire June 27, 2023

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX(TM) (racemic ketamine) in the U.S.

GlobeNewswire June 20, 2023

PharmaTher Holdings Provides Corporate Update

GlobeNewswire June 12, 2023

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX(TM) (Ketamine) for the Treatment of Parkinson's Disease

GlobeNewswire May 2, 2023

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

GlobeNewswire April 3, 2023

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX(TM) (Ketamine) in Parkinson's Disease

GlobeNewswire March 29, 2023

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX(TM) (Ketamine) On-Body Pump System

GlobeNewswire February 7, 2023

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

GlobeNewswire February 6, 2023

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX(TM) (Ketamine) for the Treatment of Rett Syndrome

GlobeNewswire February 2, 2023

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX(TM) (Ketamine) in Parkinson's Disease

GlobeNewswire February 1, 2023

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

GlobeNewswire January 18, 2023

PharmaTher Holdings Provides Update for KETARX(TM) (Racemic Ketamine) Development Programs and Expected Milestones for 2023

GlobeNewswire January 11, 2023

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

GlobeNewswire December 15, 2022

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at Neuroscience 2022 by the Society for Neuroscience

GlobeNewswire November 14, 2022

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

GlobeNewswire November 1, 2022

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson's Disease

GlobeNewswire October 5, 2022

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

GlobeNewswire September 29, 2022

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire September 16, 2022

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX(TM) Ketamine Patch

GlobeNewswire September 7, 2022